Registration opens for the respiratory drug delivery Asia 2013 scientific conference
The Respiratory Drug Delivery (RDD) Asia 2014 scientific conference will welcome pulmonary and nasal drug delivery experts from all over the world to Goa, India, 12–14 November 2014.
The joint organizers of the first edition of RDD Asia — Aptar Pharma and RDD Online announce the opening of registration.
Bringing the respiratory world together for the first time in Asia, RDD scientific conferences are globally regarded as the premier venue for presenting the latest advances in pulmonary and nasal drug delivery. They take place in Europe (RDD Europe) and the US (RDD US) in alternate years.
After a successful RDD US 2014 held last month in Fajardo, Puerto Rico, the respiratory world is looking forward to the first RDD Asia meeting, which showcases one of the world’s most prominent emerging markets and a growing location for inhaler and nasal spray development.
RDD Asia 2014 seeks to link Asian regulators, industrial and academic scientists, clinicians and business professionals with their international counterparts, together working toward the goal of advancing inhaled and nasal drug therapy worldwide.
RDD Asia, like its predecessors in the US and Europe, will feature lively, fresh and focused updates on respiratory drug delivery in Asia and the rest of the world.
More than 200 delegates from Asia and beyond are expected to attend the conference, which will be held at the Goa Marriott Resort & Spa in India. The meeting is jointly managed by RDD Online and Apta Pharma.
A two-day scientific symposium of the highest level in India
The RDD Asia 2014 scientific conference will feature podium sessions, scientific poster sessions, a technologyexhibition and workshop sessions focused on
global regulation of inhaled and nasal drug products
new therapeutic opportunities
generic product development
advanced drug delivery technologies
current issues in inhaled and nasal drug product testing
Expert speakers will address a blend of contemporary issues and essential background relating to pMDIs, DPIs, nebulizers, nasal sprays and emerging aerosol delivery platforms.